Shionogi & Co. announced that Mulpleta (lusutrombopag), a once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure, is now available throughout the United States. “We are very excited about the launch of Mulpleta in the United…
Shionogi Regains Full Rights To Symproic In U.S.
Shionogi & Co. has announced that effective immediately, Shionogi has regained full rights to Symproic (naldemedine) tablets 0.2 mg in the United States. As Purdue Pharma is taking significant steps to transform and diversify beyond its historical focus on opioid pain medications, Shionogi and Purdue have agreed to terminate the prior alliance for the US co-commercialization of Symproic.…